Midazolam Medical Valley 5 mg Norge - norsk - Statens legemiddelverk

midazolam medical valley 5 mg

medical valley invest ab - midazolamhydroklorid - munnvann, oppløsning - 5 mg

Midazolam Medical Valley 7.5 mg Norge - norsk - Statens legemiddelverk

midazolam medical valley 7.5 mg

medical valley invest ab - midazolamhydroklorid - munnvann, oppløsning - 7.5 mg

Midazolam Medical Valley 10 mg Norge - norsk - Statens legemiddelverk

midazolam medical valley 10 mg

medical valley invest ab - midazolamhydroklorid - munnvann, oppløsning - 10 mg

Voraxaze Den europeiske union - norsk - EMA (European Medicines Agency)

voraxaze

serb sas - glucarpidase - metabolic side effects of drugs and substances - alle andre terapeutiske produkter - voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.

Kaliumjodid Serb 65 mg Norge - norsk - Statens legemiddelverk

kaliumjodid serb 65 mg

serb s.a. - kaliumjodid - tablett - 65 mg

Upstaza Den europeiske union - norsk - EMA (European Medicines Agency)

upstaza

ptc therapeutics international limited - eladocagene exuparvovec - aminosyre-metabolisme, infiserte feil - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

Coxor 300 mg Norge - norsk - Statens legemiddelverk

coxor 300 mg

asamedic as (1) - acetylsalisylsyre - pulver og væske til mikstur, oppløsning - 300 mg

Tibsovo Den europeiske union - norsk - EMA (European Medicines Agency)

tibsovo

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiske midler - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Cisatracurium Kalceks 2 mg/ ml Norge - norsk - Statens legemiddelverk

cisatracurium kalceks 2 mg/ ml

akciju sabiedriba kalceks - cisatrakuriumbesilat - injeksjons-/infusjonsvæske, oppløsning - 2 mg/ ml

Duloxetine Medical Valley 60 mg Norge - norsk - Statens legemiddelverk

duloxetine medical valley 60 mg

medical valley invest ab - duloksetinhydroklorid - enterokapsel, hard - 60 mg